Triflorcas

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameTriflorcas
Drug Alias Namemet tyrosine kinase receptor inhibitors (Universite Aix-Marseille/SATT Sud Est/Valorpaca)TyrKMet receptor/PDGFR beta signalling inhibitors/PI3K/Akt pathway inhibitors (Universite de la Mediterranee/SATT Sud Est/Valorpaca)met tyrosine kinase receptor inhibitors (Universite de la Mediterranee/SATT Sud Est/Valorpaca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsProto-oncogene proteins c-akt inhibitorsPI3-kinase class I inhibitors +[4] 
TargetsPI3-kinase class IProto-oncogene proteins c-aktHepatocyte growth factor receptor +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAix-Marseille University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesValorpacaSATT PACA Corse SASAix-Marseille University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A